Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 18(10): 1411-1422, 2017 10.
Article
in En
| MEDLINE
| ID: mdl-28838862
Full text:
1
Database:
MEDLINE
Main subject:
Quality of Life
/
Neuroendocrine Tumors
/
Everolimus
/
Gastrointestinal Neoplasms
/
Lung Neoplasms
Type of study:
Clinical_trials
/
Etiology_studies
/
Prognostic_studies
Limits:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Year:
2017
Type:
Article